Pasireotide

• UNSPSC Description:

  Pasireotide (SOM230), a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/[1][2][3].

• Target Antigen:

  Somatostatin Receptor

• Type:

  Peptides

• Related Pathways:

  GPCR/G Protein;Neuronal Signaling

• Applications:

  Metabolism-sugar/lipid metabolism

• Field of Research:

  Cancer; Endocrinology

• Assay Protocol:

  https://www.medchemexpress.com/pasireotide.html

• Solubility:

  H2O : 20 mg/mL (adjust pH to 5)

• Smiles:

  NCCCC[C@@H](C(N[C@H]1CC2=CC=C(C=C2)OCC3=CC=CC=C3)=O)NC([C@H](NC([C@H](C4=CC=CC=C4)NC([C@H]5N(C([C@H](CC6=CC=CC=C6)NC1=O)=O)C[C@H](OC(NCCN)=O)C5)=O)=O)CC7=CNC8=C7C=CC=C8)=O

• Molecular Weight:

  1047.21

• References & Citations:

  [1]Lewis I, et, al. A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential. J Med Chem. 2003 Jun 5;46(12):2334-44.|[2]Quinn TJ, et, al. Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model. Surgery. 2012 Dec;152(6):1068-77.|[3]Imhof AK, et, al. Differential antiinflammatory and antinociceptive effects of the somatostatin analogs octreotide and pasireotide in a mouse model of immune-mediated arthritis. Arthritis Rheum. 2011 Aug;63(8):2352-62.|[4]Schmid HA, et, al. Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol. 2008 May 14;286(1-2):69-74.Basic Clin Pharmacol Toxicol. 2022 Jun 10.|J Clin Invest. 2024 October 1.|Am J Pathol. 2018 Apr;188(4):981-994.|Communications Medicine. 2, 80 (2022).|Hepatology. 2017 Oct;66(4):1197-1218.|Universidad De Salamanca. Biología y Clínica del Cáncer y Medicina Traslacional. 2022 Oct.

• Shipping Conditions:

  Blue Ice

• Clinical Information:

  Launched

• CAS Number:

  396091-73-9